Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FABP1 | P07148 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243314 | 1.00 | NR1H4 (0.36) | NR1H4HPGDPOLBALOX5APIGF1R | |
| SCHEMBL3053045 | 0.86 | FFAR1 (0.44) | NR1H4HPGDPOLBFFAR1VDR | |
| SCHEMBL13222684 | 0.86 | FFAR1 (0.44) | NR1H4HPGDPOLBFFAR1VDR | |
| SCHEMBL9903728 | 0.85 | SMN1; SMN2 (0.38) | NR1H4HPGDPOLBFFAR1MEN1 | |
| SCHEMBL9903732 | 0.76 | NR1H4 (0.38) | NR1H4HPGDPOLBFFAR1VDR | |
| SCHEMBL10291329 | 0.74 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL13243698 | 0.74 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL18959461 | 0.71 | KDM4E (0.34) | HPGDPOLBFFAR1MEN1KMT2A | |
| SCHEMBL18959433 | 0.70 | FFAR1 (0.36) | FFAR1 | |
| SCHEMBL18959425 | 0.70 | FFAR1 (0.39) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | NR1H4 29/4885HPGD 3191/4885POLB 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.